Clinical Review a Practical Approach to the Use of Etanercept
暂无分享,去创建一个
[1] B. Hutton. Biologic Treatment of Rheumatoid Arthritis and the Risk of Malignancy: Analyses From a Large US Observational Study , 2009 .
[2] R. Wallis. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. , 2008, The Lancet. Infectious diseases.
[3] K. Reich,et al. Tumor necrosis factor antagonists in the therapy of psoriasis. , 2008, Clinics in dermatology.
[4] M. Lebwohl,et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. , 2008, Journal of the American Academy of Dermatology.
[5] Steven R Feldman,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.
[6] F. Kerdel,et al. From conventional to cutting edge: the new era of biologics in treatment of psoriasis , 2008, Dermatologic therapy.
[7] G. Rimmelzwaan,et al. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination , 2007, Annals of the rheumatic diseases.
[8] A. Menter,et al. Current and future management of psoriasis , 2007, The Lancet.
[9] A. Gottlieb,et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. , 2007, Archives of dermatology.
[10] K. Papp. The safety of etanercept for the treatment of plaque psoriasis , 2007, Therapeutics and clinical risk management.
[11] S. Kazi,et al. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists , 2007, Rheumatology International.
[12] D. Furst,et al. Problems encountered during anti-tumour necrosis factor therapy. , 2006, Best practice & research. Clinical rheumatology.
[13] P. Merkel,et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. , 2006, Arthritis and rheumatism.
[14] J. S. Sánchez Carazo,et al. Safety of Etanercept in Psoriasis , 2006 .
[15] J. S. Sánchez Carazo,et al. Safety of etanercept in psoriasis: a critical review. , 2006, Drug safety.
[16] J. Hunek,et al. Etanercept injection site reaction. , 2005, Dermatology nursing.
[17] A. Nakanishi,et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.
[18] L. Jacobsson,et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.
[19] N. Zein. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. , 2005, Journal of hepatology.
[20] D. Goldsmith,et al. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. , 2005, American journal of clinical dermatology.
[21] Richard W. Martin,et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. , 2004, The Journal of rheumatology.
[22] R S Wallis,et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] F. Wolfe,et al. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.
[24] A. Gottlieb,et al. Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.
[25] M. Wener,et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.
[26] M. Braun,et al. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.
[27] M. Greene,et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.
[28] R. Day. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis , 2002, The Lancet.
[29] Najia Shakoor,et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy , 2002, The Lancet.
[30] R. Day. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. , 2002, Lancet.
[31] B. Bozkurt,et al. Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.
[32] D. Paty,et al. TNF neutralization in MS , 1999, Neurology.